State Street
RLMD icon

State Street’s Relmada Therapeutics RLMD Stock Holding History

State Street’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4M Buy
2,517,550
+2,160,510
+605% +$15.1M ﹤0.01% 2429
2026
Q1 		$2.48M Buy
357,040
+36,220
+11% +$171K ﹤0.01% 3234
2025
Q4 		$1.55M Buy
320,820
+219,000
+215% +$734K ﹤0.01% 3415
2025
Q3 		$205K Sell
101,820
-4,915
-5% -$4.71K ﹤0.01% 3908
2025
Q2 		$64.1K Hold
106,735
– – ﹤0.01% 4054
2025
Q1 		$28.8K Hold
106,735
– – ﹤0.01% 4163
2024
Q4 		$55.5K Buy
106,735
+7,500
+8% +$18.3K ﹤0.01% 4094
2024
Q3 		$322K Sell
99,235
-6,644
-6% -$21.5K ﹤0.01% 3693
2024
Q2 		$318K Sell
105,879
-5,250
-5% -$19K ﹤0.01% 3678
2024
Q1 		$517K Sell
111,129
-4,100
-4% -$19.8K ﹤0.01% 3639
2023
Q4 		$477K Hold
115,229
– – ﹤0.01% 3651
2023
Q3 		$346K Sell
115,229
-14,200
-11% -$42.2K ﹤0.01% 3763
2023
Q2 		$318K Sell
129,429
-421,667
-77% -$1.17M ﹤0.01% 3846
2023
Q1 		$1.25M Buy
551,096
+55,363
+11% +$191K ﹤0.01% 3464
2022
Q4 		$1.73M Sell
495,733
-94,401
-16% -$829K ﹤0.01% 3420
2022
Q3 		$21.8M Sell
590,134
-11,051
-2% -$306K ﹤0.01% 2153
2022
Q2 		$11.4M Buy
601,185
+155,621
+35% +$3.39M ﹤0.01% 2641
2022
Q1 		$12M Buy
445,564
+122,163
+38% +$2.53M ﹤0.01% 2719
2021
Q4 		$7.29M Sell
323,401
-2,470
-0.8% -$54.9K ﹤0.01% 3068
2021
Q3 		$8.54M Buy
325,871
+15,707
+5% +$420K ﹤0.01% 2974
2021
Q2 		$9.93M Buy
310,164
+19,579
+7% +$680K ﹤0.01% 2925
2021
Q1 		$10.2M Sell
290,585
-13,874
-5% -$485K ﹤0.01% 2732
2020
Q4 		$9.76M Buy
304,459
+2,138
+0.7% +$73.5K ﹤0.01% 2642
2020
Q3 		$11.4M Buy
302,321
+17,550
+6% +$678K ﹤0.01% 2372
2020
Q2 		$12.7M Buy
284,771
+276,371
+3,290% +$11.7M ﹤0.01% 2286
2020
Q1 		$287K Buy
+8,400
New +$339K ﹤0.01% 3532

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street's RLMD Position: Q2 2026 in Review

State Street increased its Relmada Therapeutics (RLMD) stake by 605% in Q2 2026, buying an estimated $15.1M and bringing the position to 2,517,550 shares worth $17.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2429.

State Street first reported a position in RLMD in Q1 2020 and has held it in 26 quarters since. The position peaked at $21.8M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • State Street held 2,517,550 shares of Relmada Therapeutics worth $17.4M as of Q2 2026.
  • State Street bought 2,160,510 Relmada Therapeutics shares in Q2 2026, an estimated $15.1M.
  • Relmada Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2429 holding.
  • State Street first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • State Street's Relmada Therapeutics position peaked at $21.8M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.